AuthorisedHuman Pharmacology (Phase I)- OtherInterventional

Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib

This study, called ReDiReCCT, is investigating a medicine named Vemurafenib. This medicine is already used for other health problems, but researchers want to see if it could help people with a type of brain tumour called glioma. This is an early stage, 'Phase I' trial. This means the main goals are to find out if the medicine is safe when given to people with glioma and to understand how it acts in the body. It's not designed to see how well it treats the cancer at this stage, but rather to gather important basic information before larger studies can happen. Anyone aged 18 or over, male or female, might be able to take part.

At a glance

Status

Authorised

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Enrolment target

Start

09 Dec 2025

Glioma

What is this study about?

The ReDiReReCT trial is an early study looking into a medicine called Vemurafenib. This medicine is already approved and used for different conditions, but scientists are hoping it might also be helpful for a type of brain tumour called glioma. Glioma is a serious condition where abnormal cells grow in the brain or spinal cord. Finding new ways to treat it is very important.

This particular study is a 'Phase I' trial. Think of it as the first step in testing a new use for a medicine in people. The main aims at this stage are to understand if Vemurafenib is safe for people with glioma and to learn how the body handles the medicine – for example, how much is needed and how long it stays in the body. It’s crucial to gather this safety information before the medicine can be tested in larger groups of people to see how well it works against the tumour.

By taking part, you would be helping researchers learn more about treatments for glioma. This kind of early research is vital because it lays the groundwork for future studies that could potentially lead to new and better ways to manage this condition.

Key takeaways

The study is exploring an existing medicine, Vemurafenib, for glioma.
It's an early-stage (Phase I) trial, focused on safety and how the medicine acts in the body.
Open to adults aged 18 and over, both men and women, with glioma.
Participation involves regular hospital visits for tests and to receive the study medicine.
You would be closely monitored for any side effects.
Participation is voluntary, and you can leave the study at any time.

Who may be eligible?

To join this study, people need to be at least 18 years old. There is no upper age limit, meaning older adults can also take part. Both men and women are welcome.

The study is specifically for people who have been diagnosed with glioma, which is a type of brain tumour. Because this is an early study, there might be other specific health requirements or conditions that would mean someone could or could not join. These details would be discussed with you by the study team.

It's important to remember that not everyone with glioma will be suitable for every trial. The study team will carefully check if this trial is the right fit for your specific health situation.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been diagnosed with glioma?
Are you able to attend regular hospital appointments?
Are you willing to take a study medicine and have medical tests?
Are you comfortable knowing this is an early-stage study focused on safety?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would first have a number of screening tests to make sure it's safe for you to join. If you are eligible, you would receive the study medicine, Vemurafenib, likely in tablet form. You would need to attend regular appointments at the hospital or clinic. These visits would involve check-ups, blood tests, and possibly other scans or tests to see how you are doing and how your body is responding to the medicine.

The study team will clearly explain the schedule of visits and what each appointment will involve. The total length of your participation would depend on the study plan and your individual response, and this would be discussed with you in detail.

Potential risks and benefits

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is that you would receive a new treatment that might help with your glioma, even though the main goal of this early study is to learn about safety, not effectiveness. You would also receive close medical attention and monitoring. Potential risks could include side effects from the study medicine, Vemurafenib, which the study team would explain to you in full. They would also monitor you closely for any unwanted effects. You always have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands

Common questions

What is glioma?

Glioma is a type of brain tumour that starts in the brain or spinal cord.

What is Vemurafenib?

Vemurafenib is a medicine that is already used for some other conditions, and this study is exploring if it could help people with glioma.

What is a 'Phase I' trial?

A 'Phase I' trial is an early study focused on checking the safety of a medicine and how it works in the body, rather than how well it treats the disease.

Will I definitely get better if I join this trial?

This study is mainly about safety and understanding the medicine. While there's a chance it might help, it's not guaranteed, and that's not the main goal at this early stage.

Can anyone with glioma join?

You need to be at least 18 years old. The study team will also check other health details to see if it's right for you.